Serum levels of soluble adhesion molecules in newly diagnosed acute myeloid leukemia and in complete remission suggest endothelial cell activation by myeloblasts

Tomas Kupsa, Jan Vanek, Pavel Zak, Ladislav Jebavy, Jan M. Horacek

Background and Aims. Despite high-dose multi-agent chemotherapy and allogeneic stem cell transplantation, the relapse rate of acute myeloid leukemia (AML) is high. Further, the disease is highly resistant to drugs. We speculated that deeper understanding of AML-endothelial cell interactions might provide new targets for selective modulation of the AML microenvironment and form the basis for novel treatment approaches. In this study, we evaluated levels of endothelium derived soluble adhesion molecules in active disease and in complete remission (CR) and their relationship with inflammatory cytokines.

Methods. Baseline serum levels of 25 cytokines and 5 soluble adhesion molecules were measured in 84 AML patients using biochip array technology. CR samples were evaluated in 44 patients of this cohort. The control group consisted of 15 healthy blood donors.

Results. All analytes were independent of age or disease origin. Some correlations were restricted to active AML, some were ubiquitous and some were found in remission. In active disease, E-selectin (E-SEL) and VCAM-1 correlated with leukocyte count, E-SEL correlated with P-selectin (P-SEL). Platelet count related to IL-7, EGF and VEGF but not to P-SEL. In CR, P-SEL correlated with platelet count and EGF but not with E-SEL. There was no relationship of P-SEL and E-SEL in the control group.

Conclusions. Leukemic activity is associated with a different pattern of soluble adhesion molecule levels. Both E-SEL and P-SEL may be derived from endothelial cells. Their levels correlated in active disease. E-SEL correlated with leukocyte count. In CR, P-SEL physiologically correlated with platelet count. The correlation with E-SEL was insignificant and absent in the control group. Our data suggest activation of endothelial cells in the presence of myeloblasts.

Key words: acute myeloid leukemia, cytokines, adhesion molecules, endothelial cell, complete remission

Received: July 23, 2016; Accepted: October 21, 2016; Available online: November 10, 2016

https://doi.org/10.5507/bp.2016.054

INTRODUCTION

The outcome of acute myeloid leukemia (AML) treatment is beleaguered by the high resistance of malignant clones to drugs. Cytokines and adhesion molecules have been studied as markers of immune system activation in many diseases including AML. Soluble (s) forms of adhesion molecules arise from proteolytic cleavage of surface-expressed molecules. In an earlier publication, we described the correlation of inflammatory cytokines such as tumour necrosis factor-α (TNF-α) and soluble adhesion molecule levels and our data suggested a critical role of endothelial cell activation on this process. As activated endothelial cells are a source of both platelet selectin (P-SEL) and endothelial selectin (E-SEL) and, platelets are a natural source of P-SEL (ref.), we were challenged to include changing parameters of blood count associated with remission into our statistical analyses. Experimentally, leukemic cytokines enhance endothelial cell growth in a co-culture of AML and endothelial cells. AML cells were found to trigger positive feedback loops and activate endothelial cells. Activated endothelial cells express the adhesion molecules involved in leukocyte rolling (P-SEL and E-SEL), leukocyte adhesion (VCAM-1, ICAM-1), chemo attractants MCP-1 and IL-8 (ref.). Endothelial cell activation by TNF-α was found to be followed by concomitant induction of VCAM-1, ICAM-1 and E-SEL expression and time-dependent increase in the number of myeloblasts attached to the endothelium. These interactions form the molecular basis of life threatening leukostasis and extramedullary spread of AML. Further, adhesion to activated endothelia may dramatically increase the resistance of AML to chemotherapy and negatively influence treatment outcome. In sum, AML cell susceptibility to chemotherapy is modulated by
dynamics of adhesion molecules. To provide more evidence of these interactions, we analysed the serum levels of a broad panel of cytokines, cytokine receptors, matrix metalloproteinase-9 and soluble adhesion molecules. We compared newly diagnosed (active) AML with patients in complete remission (CR). A control group of 15 healthy blood donors was used to confirm the most important findings in CR.

Despite high-dose multi-agent chemotherapy and allogeneic stem cell transplantation, the relapse rate is high and the same is true for the toxicity of commonly used high-dose treatment regimens.

We speculated that deeper understanding of AML-endothelial cell interactions might provide new targets for selective modulation of the AML microenvironment and form the basis for novel treatment approaches.

PATIENTS AND METHODS

Patients

A total of 84 newly diagnosed AML patients were studied in the period 2010 – 2015. Further details on the patient cohort are summarized in Table 1. The secondary AML patient group consisted of 32 patients with progression from myelodysplastic syndrome (n = 21), myeloproliferative diseases (n = 5), chronic myelomonocytic leukemia (n = 3) and the blastic phase of chronic myeloid leukemia (n = 3). Only patients eligible for induction chemotherapy were included. All were tested for karyotype and molecular genetic aberrations. Twenty-three patients were Fasinesin-like tyrosin kinase 3 – internal tandem duplication (FLT3-ITD) positive, mutation in NPM-1 occurred in 25 cases. Seven patients had acute promyelocytic leukemia (APL). Risk stratification was carried out according to the European Leukemia Net (ELN) recommendations4. Initial hyperleukocytosis (Leucocyte count ≥ 50 x 10^9/L or clinical signs of leukostasis) requiring leukapheresis was present in 23 cases. Patients with APL were treated with the PETHMA regimen combining Idarubicin and All-trans retinoic acid (ATRA). All other patients were induced with “3+7” induction chemotherapy consisting of Cytarabine 100 mg/m^2 per day for 7 consecutive days and Daunorubicin 90 mg/m^2 for the first 3 days of therapy in younger patients. Since the beginning of 2015, the induction dose of Daunorubicin used has been 60 mg/m^2 even in younger patients, according to recent evidence-based data modifications. In patients aged ≥ 65 years, Daunorubicin 45-60 mg/m^2 was administered, depending on patient WHO performance status. Nine patients had initial infection requiring intravenous antibiotic treatment. The study was approved by the local Ethics Committee and carried out in accordance with the current Helsinki Declaration. All patients gave their written consent to the study.

Complete remission samples

CR was evaluated according to NCCN criteria. A total of 45 patients were enrolled for evaluation in CR, 30 with primary AML and 15 with secondary AML. To ascertain deeper remission, all samples were obtained after at least 2 cycles of chemotherapy. Originally, all patients were intended for evaluation at CR but in 4 cases we failed to obtain a CR sample. Further shrinkage of the cohort was caused by disease progression or death in aplasia (n = 8), voluntary discontinuation of treatment (n = 1), intolerance to the treatment with further cytoreductive and palliative approach (low-dose cytarabin or hydroxyurea, n = 4) and a programme of sequence allogeneic stem cell transplantation ongoing on our department. In 3 cases of chemosensitivity, these patients did not meet the inclusion criteria (CR and after at least 2 cycles of chemotherapy) before final laboratory measurements. The cohort of 45 patients evaluated at CR thus comprised patients who were indicated for allogeneic stem cell transplantation. These underwent induction chemotherapy and at least 1 cycle of either consolidation or salvage therapy. The same was true for those who were not indicated for allogeneic stem cell transplant owing to low risk of AML, higher age or comorbidities.

Twenty-four patients had a molecular genetic marker of minimal residual disease (MRD). Of these, fifteen were MRD-negative at pair serum collection. In 21 cases, the MRD was evaluated using 8 colour flow cytometry. MRD negativity by flow cytometry was attained in 11/ 21 cases. One patient with unclassified myeloproliferative disorder had a platelet count of 711 x 10^9/L and positive MRD by flow cytometry. The depth of remission (or residual myeloproliferative changes in bone marrow) was not evaluated by trephine biopsy. Due to high risk of bias, this sample was excluded from further analyses. Patients after allogeneic stem cell transplantation were not included in the evaluation in CR.

Serum collection

Peripheral blood was collected in serum using separating tubes, immediately transported to the laboratory and processed within 2 h of collection by centrifugation at 1500 rpm x 5 min. All sera were collected before leukapheresis, administration of hydroxyurea or induction therapy. If specimens were not to be analysed immediately, they were stored frozen in small aliquots at below -70 °C as recommended by the Cytokine Array manufacturer. Repeat freeze/thaw cycles were avoided.

Biochip array technology

All analytes were measured by biochip array technology using chemiluminescent sandwich immunoassays applied to the Evidence Investigator analyzer (Randox Laboratories Ltd., Crumlin, UK). The Evidence Investigator biochip array technology is used to perform simultaneous quantitative detection of multiple analytes from a single patient sample. The core technology is the Randox biochip, a solid-state device containing an array of discrete test regions of immobilised antibodies, specific to different cytokines and growth factors. A sandwich chemiluminescent immunoassay was employed for the cytokine array. Increased levels of cytokine in a specimen will lead to increased binding of antibody labelled with horseradish peroxidase (HRP) and thus an increase
in the chemiluminescent signal emitted. The light signal
generated from each of the test regions on the biochip is
detected using digital imaging technology and compared
to that from a stored calibration curve. The concentration
of analyte present in the sample is calculated from the
calibration curve.

We evaluated circulating levels of the following factors:
interleukins (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-15, IL-23),
edipaludial growth factor (EGF), granulocyte-macrophage
colony stimulating factor (GM-CSF), interferon-gamma
(IFN-γ), monocytic chemotactic protein-1 (MCP-1), mac-
rphage inflammatory protein-1α (MIP-1α), matrix-met-
talloproteinase-9 (MMP-9), tumour necrosis factor alpha
(TNF-α), vascular endothelial growth factor (VEGF),
soluble IL-2 receptor-α (sIL-2Rα) and soluble receptors
for IL-6 (sIL-6R) and TNF-α type I and II (TNFR-
1,2), E-selectin (E-SEL), P-selectin (P-SEL), L-selectin
(L-SEL), intercellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1). The results
are expressed in nanograms per litre (ng/L) for cytokines
and micrograms per litre (µg/L) for adhesion molecules,
soluble cytokine receptors and MMP-9.

Leukemia-negative controls
The control group consisted of 15 healthy blood don-
ors (median age 41, range 25–58 years, 11 males). All
were free of clinical signs of infection prior to serum col-
lection, which was immediately before peripheral blood
sampling.

Statistical analysis
Statistical analysis was performed in the R statistical
programming environment, version 3.1.2 (http://www.R-
project.org). The levels of L-SEL exceeded upper limit
of the Array sensitivity in the majority of patients with
active AML, but did not exceed this limit in CR samples.
The levels of IL-23 were below the threshold limits for the
majority of patients and hence L-SEL and IL-23 were not
included in further analyses. We calculated the correla-
tions between cytokine levels, soluble adhesion molecules
and age, leucocyte count, haemoglobin levels, platelet
count, C-reactive protein (CRP) levels, albumin, lactic
dehydrogenase (LDH), APL, secondary AML, presence
of BCR/ABL, complex karyotype, FLT3-ITD and muta-
tions in NPM-1. Spearman correlations were used pair-wise
for continuous variables. To test the association between
dichotomous and continuous variables the Mann-Whitney
U test was used. Fisher’s exact test was used for pairs of
categorical variables. The Bonferroni-Holm correction for
multiple testing was applied where necessary. In all
analyses, $P = 0.05$ was considered statistically significant.

RESULTS

Influence of age, AML origin and genetic aberrations
The levels of IL-5 were higher in patients younger
than 65 years but the difference was not significant after
Bonferroni-Holm correction of $P$ value. The patients with
secondary AML were older ($P = 0.0175$) and in these
patients the FAB M2 subtype of AML was more frequent
($P = 0.0327$). We found no other significant differences
in evaluated analytes associated with age.

Normal karyotype had a close relationship with pri-
mary AML ($P = 0.0063$). The patients with normal kary-
type AML had higher leukocyte count, which was not
significant after Bonferroni-Holm correction, corrected
($P = 0.2356$). Secondary AML was significantly associ-
ated with complex karyotype ($P = 0.0383$). There was no
association of evaluated analytes with primary or second-
ary origin of the disease, karyotype, FAB subtype or ELN
risk stratification. The FLT3-ITD positive cases had lower
IL-7 levels (corrected $P = 0.0049$). The FLT3-ITD posi-
tive cases had higher E-SEL (nominal $P = 0.0225$),
which was not significant after Bonferroni-Holm correction
corrected ($P = 0.2677$). No other associations of molecular
translocation, which was immediately before peripheral blood
sampling.

Statistical analysis
Statistical analysis was performed in the R statistical
programming environment, version 3.1.2 (http://www.R-
project.org). The levels of L-SEL exceeded upper limit
of the Array sensitivity in the majority of patients with
active AML, but did not exceed this limit in CR samples.
The levels of IL-23 were below the threshold limits for the
majority of patients and hence L-SEL and IL-23 were not
included in further analyses. We calculated the correla-
tions between cytokine levels, soluble adhesion molecules
and age, leucocyte count, haemoglobin levels, platelet
count, C-reactive protein (CRP) levels, albumin, lactic
dehydrogenase (LDH), APL, secondary AML, presence
of BCR/ABL, complex karyotype, FLT3-ITD and muta-
tions in NPM-1. Spearman correlations were used pair-wise
for continuous variables. To test the association between
dichotomous and continuous variables the Mann-Whitney
U test was used. Fisher’s exact test was used for pairs of
categorical variables. The Bonferroni-Holm correction for
multiple testing was applied where necessary. In all
analyses, $P = 0.05$ was considered statistically significant.

Factors associated with blood count and adhesion molecule
levels in active AML
The leucocyte count correlated with E-SEL ($r =
0.7572$, $P = 0.0001$), VCAM-1 ($r = 0.5495$, $P = 0.0006$),
TNFR-1 ($r = 0.6143$, $P = 0.0001$), TNFR-2 ($r = 0.5919$, $P$
$= 0.0001$), LDH ($r = 0.6773$, $P = 0.0001$) and negatively with
IL-7 ($r = -0.4705$, $P = 0.0271$). The patients with initial
hyperleukocytosis had much higher levels of E-SEL than
other patients ($P = 0.0002$). The haemoglobin levels were
generally independent of other variables. Six variables had
at least weak correlation with haemoglobin levels with absolute values of “r” ranging from 0.2012 to 0.3663,
but none of them was statistically significant. The plate-
let count correlated with IL-7 ($r = 0.6845$, $P = 0.0001$),
EGF ($r = 0.7060$, $P = 0.0001$) and VEGF ($r = 0.5211$, $P$
$= 0.0025$). The EGF levels correlated with VEGF ($r =
0.4615$, $P = 0.0396$). The levels of soluble adhesion mol-
ecules correlated. Their correlations with other factors
are summarized in Table 2.

Inflammatory markers and other correlations in active
AML
The CRP levels correlated strongly with IL-6 ($r =
0.7095$, $P = 0.0001$), ICAM-1 ($r = 0.5438$, $P = 0.0014$),
TNF-α correlated positively with TNFR-1 and negatively with albumin levels ($r = -0.4806$, $P = 0.0175$). Correlations
of IL-6 with ICAM-1 and TNFR-1 were close to statistical
significance ($r = 0.4496$, $P = 0.0646$) and ($r = 0.4438$, $P$
$= 0.0815$) respectively. The IL-1α correlated with IL-2 ($r =
0.4556$, $P = 0.0506$) and IL-4 ($r = 0.5039$, $P = 0.0059$).
The levels of TNF-α correlated positively with TNFR-2
($r = 0.5377$, $P = 0.0011$), but not with TNFR-1 ($r = 0.3004$, $P = 0.0001$), TNFR-2 correlated with TNFR-1 ($r =
0.6442$, $P = 0.0001$) and sIL-6R ($r = 0.5721$, $P = 0.0001$).
IL-3 correlated with IL-12 ($r = 0.4624$, $P = 0.0001$), IL-

94
Table 1. Baseline characteristics of studied group.

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Primary AML</th>
<th>Secondary AML</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>84</td>
<td>52 (62 %)</td>
<td>32 (38 %)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>53.3 ± 12.2</td>
<td>49.3 ± 12.3</td>
<td>59.8 ± 9.2</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>34 (40 %)</td>
<td>22 (42 %)</td>
<td>12 (37 %)</td>
</tr>
<tr>
<td>Female</td>
<td>50 (60 %)</td>
<td>30 (58 %)</td>
<td>20 (63 %)</td>
</tr>
<tr>
<td>Cytogenetics (risk)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>18</td>
<td>17</td>
<td>1</td>
</tr>
<tr>
<td>Intermediate</td>
<td>29</td>
<td>18</td>
<td>11</td>
</tr>
<tr>
<td>High</td>
<td>37</td>
<td>17</td>
<td>20</td>
</tr>
<tr>
<td>Leucocyte count (x 10^9/L), median</td>
<td>50.7 ± 57.3</td>
<td>48.1 ± 50.1</td>
<td>54.8 ± 69.4</td>
</tr>
<tr>
<td>FAB type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>8</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>M1</td>
<td>17</td>
<td>11</td>
<td>6</td>
</tr>
<tr>
<td>M2</td>
<td>32</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>M3</td>
<td>7</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>M4</td>
<td>12</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>M5</td>
<td>7</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>M7</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Active infection</td>
<td>9 (11 %)</td>
<td>4 (8 %)</td>
<td>5 (16 %)</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>47.1 ± 48.4</td>
<td>39.3 ± 37.1</td>
<td>59.0 ± 68.2</td>
</tr>
<tr>
<td>FLT3-ITD</td>
<td>23 (21 %)</td>
<td>18 (35 %)</td>
<td>5 (16 %)</td>
</tr>
<tr>
<td>NPM-1 mutated</td>
<td>25 (30 %)</td>
<td>22 (42 %)</td>
<td>3 (9 %)</td>
</tr>
<tr>
<td>BCR-ABL</td>
<td>3 (4 %)</td>
<td>0</td>
<td>3 (9 %)</td>
</tr>
<tr>
<td>Complex karyotype</td>
<td>10 (12 %)</td>
<td>3 (6 %)</td>
<td>7 (22 %)</td>
</tr>
</tbody>
</table>

Table 2. Correlations of soluble adhesion molecule levels with other factors in active AML.

<table>
<thead>
<tr>
<th>Analyte</th>
<th>VCAM-1</th>
<th>P</th>
<th>ICAM-1</th>
<th>P</th>
<th>E-SEL</th>
<th>P</th>
<th>P-SEL</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>VCAM-1</td>
<td>-</td>
<td>0.5993</td>
<td>&lt; 0.0001</td>
<td>0.5363</td>
<td>0.0011</td>
<td>0.4406</td>
<td>0.0922</td>
<td></td>
</tr>
<tr>
<td>ICAM-1</td>
<td>0.5993</td>
<td>&lt; 0.0001</td>
<td>-</td>
<td>0.4693</td>
<td>0.0285</td>
<td>0.2058</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>E-SEL</td>
<td>0.5363</td>
<td>0.0011</td>
<td>0.4693</td>
<td>0.0285</td>
<td>-</td>
<td>0.6087</td>
<td>&lt; 0.0001</td>
<td>-</td>
</tr>
<tr>
<td>P-SEL</td>
<td>0.4406</td>
<td>0.0922</td>
<td>0.2058</td>
<td>1</td>
<td>0.6087</td>
<td>&lt; 0.0001</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Leucocyte count</td>
<td>0.5495</td>
<td>0.0066</td>
<td>0.4171</td>
<td>0.2251</td>
<td>0.7572</td>
<td>&lt; 0.0001</td>
<td>0.4407</td>
<td>0.0918</td>
</tr>
<tr>
<td>LDH</td>
<td>0.6005</td>
<td>&lt; 0.0001</td>
<td>0.4649</td>
<td>0.0344</td>
<td>0.7545</td>
<td>&lt; 0.0001</td>
<td>0.4499</td>
<td>0.0640</td>
</tr>
<tr>
<td>CRP</td>
<td>0.0249</td>
<td>1</td>
<td>0.4885</td>
<td>0.0122</td>
<td>0.0980</td>
<td>1</td>
<td>-0.2883</td>
<td>1</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.1856</td>
<td>1</td>
<td>0.4496</td>
<td>0.0646</td>
<td>0.1036</td>
<td>1</td>
<td>-0.1999</td>
<td>1</td>
</tr>
<tr>
<td>TNFα</td>
<td>0.6474</td>
<td>&lt; 0.0001</td>
<td>0.4288</td>
<td>0.1453</td>
<td>0.3468</td>
<td>1</td>
<td>0.3445</td>
<td>1</td>
</tr>
<tr>
<td>TNFR-1</td>
<td>0.5086</td>
<td>0.0047</td>
<td>0.5466</td>
<td>0.0007</td>
<td>0.4837</td>
<td>0.0152</td>
<td>0.2455</td>
<td>1</td>
</tr>
<tr>
<td>TNFR-2</td>
<td>0.6076</td>
<td>&lt; 0.0001</td>
<td>0.4431</td>
<td>0.0835</td>
<td>0.4773</td>
<td>0.0202</td>
<td>0.2835</td>
<td>1</td>
</tr>
<tr>
<td>sIL-2Rα</td>
<td>0.4749</td>
<td>0.0224</td>
<td>0.2189</td>
<td>1</td>
<td>0.1835</td>
<td>1</td>
<td>0.1821</td>
<td>1</td>
</tr>
<tr>
<td>sIL-6R</td>
<td>0.4733</td>
<td>0.0240</td>
<td>0.2507</td>
<td>1</td>
<td>0.3612</td>
<td>1</td>
<td>0.2539</td>
<td>1</td>
</tr>
<tr>
<td>MMP-9</td>
<td>0.3545</td>
<td>1</td>
<td>0.0545</td>
<td>1</td>
<td>0.4114</td>
<td>0.2769</td>
<td>0.4842</td>
<td>0.0149</td>
</tr>
</tbody>
</table>

r - Spearman correlation coefficient
P - Bonferroni-Holm corrected values for multiple testing

13 (r = 0.5396, P = 0.0010) and GM-CSF (r = 0.4527, P = 0.0570). The levels of IL-12 and IL-13 correlated (r = 0.5038, P = 0.0060). GM-CSF correlated with IL-5 (r = 0.6419, P = 0.0001). No other correlations were statistically significant.

Changes of evaluated analytes in complete remission
Achieving CR was associated with normalisation of leukocyte count and platelet levels, improved haemoglobin levels, normalisation of LDH, CRP and better albumin levels. In CR, the levels of EGF, VEGF and IL-7 were higher than in active AML. In contrast, the levels of IL-6, IL-8, sIL-6R and TNFR-1 were lower in CR. All these changes are summarised in Table 3. The increase in CR levels of P-SEL and MMP-9, same as the decrease of E-SEL, IL-5, IL-10, IL-15, IFN-γ, GM-CSF, and sIL-2Rα was not significant after P value correction for multiple testing.
Correlation analysis in complete remission

Leukocyte count correlated negatively with IL-3 (r = -0.6772, P = 0.0179). There was no correlation of leukocyte count with VCAM-1 (r = 0.0097) and correlation with E-SEL was weak (r = 0.2686) and insignificant. Haemoglobin levels correlated with L-SEL (r = 0.6662, P = 0.0268) and MMP-9 (r = 0.5185). Platelet count correlated with P-SEL (r = 0.6161) and IL-7 (r = 0.6215).

VCAM-1 correlated with ICAM-1 (r = 0.5379), TNFR-1 (r = 0.5768, P = 0.9925) and TNFR-2 (r = 0.5425). ICAM-1 correlated with TNFR-1 (r = 0.4837). There was no relationship between immunoglobulin and selectin adhesion molecules. The correlation of E-SEL with P-SEL, like the correlations of these adhesion molecules with L-SEL, were weak to moderate but not statistically significant.

Other correlations

TNFR-2 correlated with TNFR-1 (r = 0.7413, P = 0.0012) and sIL-6R (r = 0.5533). P-SEL levels correlated with EGF (r = 0.5677, P = 0.5343). VEGF moderately correlated with TNF-α (r = 0.4922) and IL-7 (r = 0.4125), which were not statistically significant. IL-1α correlated strongly with IL-1β (r = 0.6274, P = 0.0987). Both correlated with IL-2. For IL-1α the correlation was moderate with r = 0.5237, IL-1β correlated strongly with r = 0.7160 (P = 0.0037). All three cytokines correlated with IL-4 with r = 0.4819 for IL-1α, r = 0.5938 for IL-1β and r = 0.6956 (P = 0.0088) for IL-2. CRP correlated with IL-6 (r = 0.6000, P = 0.2235) and TNF-α (r = 0.5247). Albumin correlated negatively with IL-6 (r = -0.4118) and TNF-α (r = -0.5633). Leaving an outlier sample with elevated CRP (45mg/L) out of the analysis affected the correlation of CRP and TNF-α (r = 0.3188) and correlations with albumin levels. Correlations of other factors were not affected by excluding this sample from of the analysis. GM-CSF strongly correlated with IL-5 (r = 0.7319), IL-6 (r = 0.0018) and further with IL-1α (r = 0.5129), but not with IL-3. Correlations of IL-3 with IL-12 and IL-13, like the correlation of IL-12 and IL-13 were weak and not significant.

Cytokines and adhesion molecules in control group samples

Compared to CR measures, the levels of IL-4 (P = 0.0018) and GM-CSF (P = 0.0462) were higher in the control group. The levels of VCAM-1 (P = 0.0014), ICAM-1 (P = 0.0162) and IL-7 (P = 0.0444) were lower in the control group than in remission samples. The levels of VCAM-1 correlated with ICAM-1 (r = 0.5607) and ESEL (r = 0.5344). E-SEL levels had no relationship with P-SEL (r = 0.0626). P-SEL correlated with IL-7 (r = 0.6127), IL-8 (r = 0.6425), EGF (r = 0.7614) and VEGF (r = 0.5572). The correlations of EGF with IL-7 (r = 0.8758, P = 0.0087) and IL-8 (r = 0.8559, P = 0.0218) were very strong, like the correlation of VEGF and TNF-α (r = 0.8093, P = 0.1192). IL-7 correlated with IL-8 (r = 0.6864). IL-1α correlated with IL-4 (r = 0.7739) and MCP-1 (r = 0.7224). MCP-1 correlated with GM-CSF (r = 0.6766) and MIP-1α (r = 0.7013). TNFR-1 correlated with TNFR-2 (r = 0.6115) and sIL-6R (r = 0.6351). Based on these results, we identified correla-
tions that are ubiquitous (with slight modifications) and correlations restricted to active disease or on the other hand to CR/healthy controls, see Table 4.

DISCUSSION

Better understanding of the cancer microenvironment is a sine qua non for development of new treatment approaches. In vitro experiments published so far, like our previous results, demonstrate that cytokines and adhesion molecules form a unique interacting functional network\textsuperscript{9,10}. Overexpression of cytokines in acute myeloid leukemia patients declines after chemotherapy or remission. Here we report that simple comparison of cytokine and adhesion molecule levels in active acute leukemia and complete remission may cause misleading conclusions. Correlation analysis provides a plethora of information. Adding blood count and basic inflammatory markers to the analyses was very helpful in revealing the complexity of the system in active AML which is regulated by different principles than in CR.

In newly diagnosed AML, the levels of IL-7, EGF and VEGF correlated with platelet count and E-SEL correlated with P-SEL. The levels of P-SEL increased in CR (which was not significant after P correction for multiple testing) and compared to active AML P-SEL no longer correlated with E-SEL levels, which were decreased. To explain these findings, we formed a hypothesis of two independent simultaneous processes.

First, achievement of CR leads to improvement in baseline thrombocytopenia, which causes significant increase in platelet related cytokines (IL-7, EGF, VEGF). The literature suggests these cytokines are stored in platelet granules\textsuperscript{11-13}, which explains their correlation with platelet count. In CR, P-SEL correlates with platelet count, which is probably due to physiological cleavage of surface P-SEL from platelets, and further with IL-8. IL-8 (CXCL8) was independent of other evaluated factors in acute disease and rapidly decreased in CR, see Table 3. These findings confirm the viability of using IL-8 as a marker of leukemic cell burden, reported previously\textsuperscript{14}. CRP levels of IL-8 were associated with platelet count. Based on the published data, this association may originate from either direct storage of IL-8 in platelets, or indirectly by secretion of IL-8 by endothelial cells induced by activated platelets\textsuperscript{15,16}.

Second, in active AML, the levels of adhesion molecules correlated with leukocyte count, levels of TNF-α, TNFR-1 and TNFR-2. ICAM-1 had a relationship with CRP levels, which were elevated in newly diagnosed patients. Myeloblasts are reported to stimulate endothelial cells in vitro\textsuperscript{4}. Our data harvested from in vivo analyses are in agreement with in vitro findings. Further, our analysis included platelet count and P-SEL levels. Both E-SEL and P-SEL can be produced by endothelial cells. Here we report that significant correlations of E-SEL and VCAM-1 with leukocyte count and correlation of E-SEL and P-SEL, are the most important findings for confirming activation of endothelial cells in the presence of myeloblasts. Adhesion receptors and TNF-α secreted by blast cells play central roles in these reactions. The activation of endothelial cell declines in CR. The correlation of P-SEL and E-SEL, present in active AML, was weak and statistically insignificant. In the control group, this correlation was absent, showing possible artifacts in the background of hematopoiesis reconstitution in CR samples after chemotherapy. Further, we found no relation with leukemia origin or subtype. We consider the endothelial cell activation by myeloblasts is a uniform reaction of endothelial cells to inflammatory stimuli originating from AML activity, irrespective of age or AML origin. In this dataset, only FLT3-ITD positive leukemias had lower IL-7 levels than other cases, which were probably not linked to endothelial cell activation. There is no clear association of lower IL-7 levels and the adverse biology of these leukemias and this requires further investigation. We did not include correlations of soluble adhesion molecule levels and absolute blast count, which might be more exact but cannot be applied to CR samples. Adhesion of myeloblasts to narrow stromal cells or activated endothelial cells is the background of resistance to chemotherapy\textsuperscript{17}. Mechanical changes of activated endothelial cells induced by myeloblasts of leukemic cell lines HL-60 and KG-1 have been reported recently\textsuperscript{18}. Thus, blocking AML cell interactions with endothelium or narrow stromal elements may have ameliorating effects for the majority of AML cases.

The origin of elevated CRP levels in this dataset is unclear in the majority of cases. Nine out of 84 patients had clinical signs of infection at AML diagnosis. Infectious complications are frequent in these patients. The baseline laboratory investigations were carried out according to the statutory recommendations of our department. Procalcitonin levels are not routinely measured and leukemic production of IL-6 is frequent in AML (ref.\textsuperscript{19}). Thus, it was not possible to distinguish elevation in CRP due to occult infection from that caused by myeloblast activity. On the other hand, only IL-6 and ICAM-1 levels were significantly associated with CRP levels in newly diagnosed AML. The decrease in albumin levels in inflammation and its negative correlation with CRP levels is a common pathophysiological event. In our study, higher CRP was commonly found in newly diagnosed cases, and had no significant relationship with the vast majority of evaluated analytes.

Our data show correlations (with slight modifications) that are ubiquitous and correlations restricted to active disease or on the other hand to CR/healthy controls, see Table 4. Correlations largely influenced by platelet count were in levels of IL-7, EGF, VEGF and P-SEL in remission. We were unable to confirm this in the controls as blood count parameters were not collected at the time of sampling. Still, the strong correlations of P-SEL with IL-7, IL-8 and EGF and very strong correlation of EGF with IL-7 and IL-8 suggest association with platelet count. For this reason, we consider adding of control group into analyses worth even without exact blood count analysis in these subjects.

In CR, the leukocyte count strongly negatively correlated with IL-3 levels. We consider the above correlation
quite surprising. IL-3 stimulates the differentiation of multipotent hematopoietic stem cells into myeloid progenitor cells or, with the addition of IL-7, into lymphoid progenitor cells. For this reason we would expect positive correlation if any. To verify this finding, analysis in durable complete remission (at circa 6 months after last chemotherapy in patients not treated with allogeneic stem cell transplantation) or analysis of a sufficient control group including blood count parameters should be performed.

The L-SEL, despite exceeding the upper limit of array sensitivity in the majority of AML samples, significantly decreased in CR. In CR, it strongly correlated with haemoglobin levels. L-SEL is the smallest of selectin adhesion molecules and acts as a "homing receptor" for lymphocytes to enter secondary lymphoid tissues via high endothelial venules. Despite meticulous effort, we found no evidence of a relationship between soluble L-SEL and haemoglobin levels in healthy individuals. The literature describes elevated L-SEL levels following exertion in sickle cell trait carriers\(^4\), but this article was not aimed at correlation of haemoglobin levels with L-SEL or L-SEL origin. To explain this finding we suggest that L-SEL may non-covalently adhere to erythrocyte surface.

This study was an investigation of the interplay between AML activity and levels of endothelial derived soluble adhesion molecules, which enabled us to analyse their interaction indirectly in vivo. Our data show that endothelial cells are activated in the presence of myeloblasts and this is independent of disease origin or age. The activation declined rapidly in CR with restoration of normal hematopoiesis. The results and sufficient published data are convincing evidence that targeting these interactions is feasible in the majority of patients and increase AML sensitivity to treatment. The goal of this study was not the prognostic significance of the factors evaluated but such assessment is underway and will be completed in the near future. It was beyond the scope of this study to evaluate the differences in analytes between CR samples and the control group. The latter would provide more evidence for the long-term effects of chemotherapy on human hematopoiesis. Such analyses would require a larger control group of MRD negative patients, preferably in durable CR. We intend to carry out this analysis with a larger cohort of patients and healthy controls.

Acknowledgement: The work was supported by a specific research project "Analysis of defined prognostic factors in acute myeloid leukemia" (FMHS Hradec Kralove), by a long-term organisation development plan 1011 (FMHS Hradec Kralove) and by MH CZ – DRO (UHHK, 00179906).

Author contributions: TK: literature search, research design, statistical analysis, manuscript writing; JV: statistical analysis; PZ, LJ: critical revision; JMH: research design, statistical analysis, manuscript writing, critical revision.

Conflict of interest statement: The authors state that there are no conflicts of interest regarding the publication of this article.

REFERENCES